<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>PURPOSE: Cyclooxygenase (COX)-2 has been causally implicated in <z:e sem="disease" ids="C0596263" disease_type="Neoplastic Process" abbrv="">carcinogenesis</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>The evidence for increased COX-2 in the malignant progression of <z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo> is contradictory </plain></SENT>
<SENT sid="2" pm="."><plain>We hypothesize that COX-2 expression may be causally affected by the gastrin status via the cholecystokinin 2 (CCK(2)) receptor </plain></SENT>
<SENT sid="3" pm="."><plain>EXPERIMENTAL DESIGN: COX-2 and <z:chebi fb="11" ids="26333">prostaglandin</z:chebi> E(2) expression were evaluated by Western blotting and enzyme-linked immune assay in samples of squamous esophagus, <z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo> with varying degrees of <z:mpath ids='MPATH_589'>dysplasia</z:mpath> to <z:mp ids='MP_0009308'>adenocarcinoma</z:mp>, and <z:mpath ids='MPATH_458'>normal</z:mpath> duodenum </plain></SENT>
<SENT sid="4" pm="."><plain>Differentiation status was evaluated by histopathology and villin expression </plain></SENT>
<SENT sid="5" pm="."><plain>A longitudinal case-control study compared COX-2 in patients who progressed to <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> with nonprogressors matched for age and length of follow-up </plain></SENT>
<SENT sid="6" pm="."><plain><z:chebi fb="5" ids="33699">Messenger RNA</z:chebi> levels of gastrin and CCK(2) receptor in biopsies and cell lines were evaluated by reverse transcription-PCR, and in vitro gastrin stimulation was conducted with and without inhibitors for CCK(2) (YM022) and COX-2 (NS-398) </plain></SENT>
<SENT sid="7" pm="."><plain>Cell proliferation was evaluated using minichromosome maintenance protein 2 (Mcm2) and <z:chebi fb="0" ids="53233">3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide</z:chebi> assays </plain></SENT>
<SENT sid="8" pm="."><plain>RESULTS: COX-2 expression is significantly increased in <z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo> before <z:mpath ids='MPATH_589'>dysplasia</z:mpath> development </plain></SENT>
<SENT sid="9" pm="."><plain>Expression is highly variable within Barrett's <z:mpath ids='MPATH_589'>dysplasia</z:mpath> and <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> samples independent of differentiation status </plain></SENT>
<SENT sid="10" pm="."><plain>In a longitudinal case-control study, the expression levels within patients increased over time, regardless of the degree of malignant progression </plain></SENT>
<SENT sid="11" pm="."><plain>Biopsies from nondysplastic <z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo> expressed increased gastrin <z:chebi fb="2" ids="33699">mRNA</z:chebi> levels compared with other biopsies </plain></SENT>
<SENT sid="12" pm="."><plain>Gastrin significantly induced COX-2, <z:chebi fb="11" ids="26333">prostaglandin</z:chebi> E(2), and cell proliferation in biopsies and cell lines </plain></SENT>
<SENT sid="13" pm="."><plain>Gastrin-induced proliferation can be inhibited by YM022 and NS-398 </plain></SENT>
<SENT sid="14" pm="."><plain>CONCLUSIONS: COX-2 is up-regulated early in the Barrett's <z:mpath ids='MPATH_160'>metaplasia</z:mpath> sequence </plain></SENT>
<SENT sid="15" pm="."><plain>During <z:e sem="disease" ids="C0596263" disease_type="Neoplastic Process" abbrv="">carcinogenesis</z:e>, gastrin is a significant determinant of COX-2 activity levels via the CCK(2) receptor </plain></SENT>
</text></document>